Intervention not reported
Time to first exacerbation requiring intravenous antibiotics · adults and children with cystic fibrosis
1 finding from 1 review
Use of ET (≥ 1); all studies · neonates with alloimmune hemolytic disease
It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of ET (≥ 1); all studies compared with phototherapy alone (very low certainty).
1 finding from 1 review
Use of ET (≥ 1); placebo‐controlled studies · neonates with alloimmune hemolytic disease
Intravenous immunoglobulin plus phototherapy showed no clear difference in use of ET (≥ 1); placebo‐controlled studies compared with phototherapy alone (moderate certainty).
1 finding from 1 review
ETs performed per infant; all studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
ETs performed per infant; placebo‐controlled studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
Use of top‐up transfusion in 1st week of life; all studies · neonates with alloimmune hemolytic disease
Intravenous immunoglobulin plus phototherapy showed no clear difference in use of top‐up transfusion in 1st week of life; all studies compared with phototherapy alone (low certainty).
1 finding from 1 review
Use of top‐up transfusion after 1st week of life; all studies · neonates with alloimmune hemolytic disease
It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of top‐up transfusion after 1st week of life; all studies compared with phototherapy alone (very low certainty).
1 finding from 1 review
Maximum total serum bilirubin (µmol/L); all studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
Proportion of people with hospital admissions (from the emergency room) · acute exacerbations of chronic obstructive pulmonary disease
Intravenous magnesium sulfate + standard care may leads to lower proportion of people with hospital admissions (from the emergency… compared with placebo + standard care (low certainty).
1 finding from 1 review
Proportion of people requiring non‐invasive ventilation · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether intravenous magnesium sulfate + standard care changes proportion of people requiring non‐invasive ventilation compared with placebo + standard care (very low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Length of hospital stay · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in oxygen saturation (SaO2) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
BMD: % change in BMD at the lumbar spine · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in volumetric BMD of distal radius or tibia · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in fracture frequency · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Number of participants reporting an adverse event · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in NTX (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review